Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergio Fazio

Showing results (1-10 of 284) with videos related to

Pageof 29
Sort By:
Clinical Therapeutics|March 18, 2008
Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapySergio Fazio
Cardiovascular Drugs and Therapy|January 23, 2009
More clinical lessons from the FIELD studySergio Fazio
Atherosclerosis. Supplements|February 10, 2015
The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibeSergio Fazio
Circulation Research|August 16, 2014
Peeking into a cool future: genome editing to delete PCSK9 and control hypercholesterolemia in a single shotSergio Fazio, Hagai Tavori
The New England Journal of Medicine|March 24, 2006
Failure of ACAT inhibition to retard atherosclerosisSergio Fazio, MacRae Linton
Circulation Research|May 8, 2020
Lipoprotein(a) Gets WorseNathalie Pamir, Sergio Fazio
Circulation Research|September 3, 2016
HDL Particle Size and Functional HeterogeneitySergio Fazio, Nathalie Pamir
Journal of Clinical Lipidology|December 3, 2010
High-density lipoprotein therapeutics and cardiovascular preventionSergio Fazio, Macrae F Linton
Current Opinion in Lipidology|September 28, 2002
Cyclooxygenase-2 and atherosclerosisMacRae F Linton, Sergio Fazio
F1000Research|March 17, 2017
Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular diseaseMichael D Shapiro, Sergio Fazio
Pageof 29

Showing results (1-10 of 284) with videos related to

Sort By:
Pageof 29
Clinical Therapeutics|March 18, 2008
Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapySergio Fazio
Cardiovascular Drugs and Therapy|January 23, 2009
More clinical lessons from the FIELD studySergio Fazio
Atherosclerosis. Supplements|February 10, 2015
The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibeSergio Fazio
Circulation Research|August 16, 2014
Peeking into a cool future: genome editing to delete PCSK9 and control hypercholesterolemia in a single shotSergio Fazio, Hagai Tavori
The New England Journal of Medicine|March 24, 2006
Failure of ACAT inhibition to retard atherosclerosisSergio Fazio, MacRae Linton
Circulation Research|May 8, 2020
Lipoprotein(a) Gets WorseNathalie Pamir, Sergio Fazio
Circulation Research|September 3, 2016
HDL Particle Size and Functional HeterogeneitySergio Fazio, Nathalie Pamir
Journal of Clinical Lipidology|December 3, 2010
High-density lipoprotein therapeutics and cardiovascular preventionSergio Fazio, Macrae F Linton
Current Opinion in Lipidology|September 28, 2002
Cyclooxygenase-2 and atherosclerosisMacRae F Linton, Sergio Fazio
F1000Research|March 17, 2017
Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular diseaseMichael D Shapiro, Sergio Fazio
Pageof 29